These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 12902862)
1. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Crane CH; Mason K; Janjan NA; Milas L Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862 [TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. Rich TA; Shepard R Am J Clin Oncol; 2003 Aug; 26(4):S110-3. PubMed ID: 12902867 [TBL] [Abstract][Full Text] [Related]
3. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Liao Z; Milas L; Komaki R; Stevens C; Cox JD Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863 [TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565 [TBL] [Abstract][Full Text] [Related]
5. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Nakata E; Mason KA; Hunter N; Husain A; Raju U; Liao Z; Ang KK; Milas L Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):369-75. PubMed ID: 14751505 [TBL] [Abstract][Full Text] [Related]
6. [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine]. Hada M; Mizutari K Gan To Kagaku Ryoho; 2004 Jun; 31(6):959-61. PubMed ID: 15222121 [TBL] [Abstract][Full Text] [Related]
8. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097 [TBL] [Abstract][Full Text] [Related]
10. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Cascinu S; Scartozzi M; Carbonari G; Pierantoni C; Verdecchia L; Mariani C; Squadroni M; Antognoli S; Silva RR; Giampieri R; Berardi R Am J Clin Oncol; 2007 Oct; 30(5):526-30. PubMed ID: 17921715 [TBL] [Abstract][Full Text] [Related]
16. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Davis TW; O'Neal JM; Pagel MD; Zweifel BS; Mehta PP; Heuvelman DM; Masferrer JL Cancer Res; 2004 Jan; 64(1):279-85. PubMed ID: 14729635 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525 [TBL] [Abstract][Full Text] [Related]
18. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs. Housholder GT; Chan JT J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801 [No Abstract] [Full Text] [Related]
19. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. El-Rayes BF; Ali S; Sarkar FH; Philip PA Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]